Morgan Stanley (NYSE:MS) analyst Matthew Harrison maintained a Buy rating on Genmab (NASDAQ:GMAB) A/S on Tuesday, setting a price target of $35, which is approximately 8.21% below the present share price of $38.13.
Harrison expects Genmab A/S to post earnings per share (EPS) of $5.19 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Genmab, with an average price target of $37.5.
The analysts price targets range from a high of $42 to a low of $32.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $5.45 billion and a net profit of $4.5 billion. The company's market cap is $24.91 billion.
According to TipRanks.com, Morgan Stanley analyst Matthew Harrison is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.1% and a 62.50% success rate.
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its portfolio includes two products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.